AYA

Artrya

Health Care Equipment & Services

Artrya Limited is a cutting-edge medical technology company specializing in software that automates the analysis of heart CT scans to aid in the diagnosis of Coronary Artery Disease. Positioned as an innovator in healthcare AI solutions, Artrya focuses on providing accurate, non-invasive diagnostic tools that enhance patient care outcomes. Their offerings are particularly valuable in improving the...

medical technology

heart disease

AI software

healthcare innovation

Shorted

short percentage0.32%

reported shorts501.8K

shares on issue158.084M

About

website

artrya.com

industry

Health Care Equipment & Services

address

1257 Hay Street, WEST PERTH, WA, AUSTRALIA, 6005

Connect

Key Metrics

market cap

$578.48M

price$3.65

eps$-0.18

More Health Care Equipment & Services Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

medical technology

heart disease

AI software

healthcare innovation

diagnostics

Company Overview

AI-generated company summary

Company History

Founded in 2018, Artrya Limited has rapidly evolved into a significant player within the healthcare and diagnostics technology space. A key milestone was their listing on the Australian Stock Exchange in November 2021. Since its inception, Artrya has focused on leveraging artificial intelligence and deep learning technologies to improve the early detection of heart disease, a leading cause of death worldwide. The company's strategic collaboration with hospitals and clinics has enhanced its product development and market reach.

Competitive Advantages

Artrya's diagnostic software utilizes proprietary AI algorithms, providing a unique advantage in the speed and accuracy of coronary artery disease detection. Their collaborations with top healthcare institutions enable real-world clinical data validation, further enhancing their product's credibility. Furthermore, the company has a strong focus on patient-centric innovation, aligning its product development with clinical needs and regulatory standards.

Risk Factors

•The reliance on rapid technological advancement could pose risks if competitors outperform in AI technology development.
•Regulatory changes in healthcare diagnostics could impact product deployment and market access.
•Market acceptance and adoption of AI-based diagnostics in conservative medical environments might be slower than anticipated.

Recent Developments

Last 6 months

In the past six months, Artrya announced a partnership with international healthcare providers to enhance the implementation of their AI software in clinical settings. They reported strong results in test settings showing improved diagnostic accuracy for coronary conditions. Additionally, the company has been focusing on expanding its presence in European markets seeking regulatory approvals.

Key People

Leadership team at Artrya

John S. Hodgkinson

CEO

John S. Hodgkinson is the CEO of Artrya Limited, bringing over two decades of executive experience in the healthcare sector. His leadership is focused on integrating AI into diagnostic processes to revolutionize patient outcomes.

Gareth P. Jones

CFO

Gareth P. Jones serves as the CFO of Artrya Limited, with extensive expertise in financial management and strategy within technology companies. His role is pivotal in driving financial planning and supporting the company's growth strategy.